Unicycive Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; filed August 14, 2023. Unicycive is a clinical-stage biotechnology company developing Oxylanthanum Carbonate for hyperphosphatemia in chronic kidney disease and UNI 494 for acute kidney injury. It had no product sales.
Financial performance and liquidity
| Metric | Q2 2023 | Six months 2023 |
|---|---|---|
| Revenue | $0 | $675,000 licensing revenue |
| Research and development expense | $2.267 million | $5.297 million |
| General and administrative expense | $2.055 million | $3.902 million |
| Net loss | $3.838 million | $18.413 million |
| Net loss per common share | $0.29 | $1.26 |
| Operating cash used | Not separately stated | $9.422 million |
- Cash and cash equivalents were $18.818 million at June 30, 2023, compared with $455,000 at year-end 2022. Net cash from financing was $27.797 million, mainly from the March preferred-stock financing.
- Current assets were $21.930 million and current liabilities $15.419 million. Current liabilities include a $12.924 million warrant liability; the filing reports no conventional borrowing balance. Operating lease liabilities totaled $937,000, of which $303,000 was current.
- In March, the company issued 30,190 Series A-1 preferred shares for $30.190 million gross proceeds and approximately $28.0 million net proceeds. The warrant liability’s $10.093 million six-month fair-value increase was a noncash expense that materially increased reported net loss.
Changes versus prior comparable periods
- Q2 operating expenses rose 19% year over year to $4.322 million; R&D increased 22% and G&A increased 16%. Q2 net loss was $3.838 million versus $3.636 million.
- Six-month operating expenses increased 28% to $9.199 million, partly reflecting higher drug-development costs. Licensing revenue of $675,000 came from the February 2023 Lotus agreement; there was no comparable revenue in the prior-year period.
- Six-month net loss rose to $18.413 million from $7.173 million, primarily reflecting the $10.093 million warrant fair-value expense, alongside higher operating costs. Operating cash use increased from $6.004 million to $9.422 million.
Outlook, risks and unusual items
- Management said funding would be needed before the end of Q2 2024 at the anticipated spending rate. The filing states there is substantial doubt about the company’s ability to continue as a going concern for one year after the financial statements became available. Additional financing may be unavailable or dilutive; a shortfall could force reductions or delays to development programs.
- Recent FDA feedback may require a clinical trial, but its scope and financial impact were uncertain. Management expected clarifying FDA feedback in fall 2023. The company also expects R&D spending to increase as it advances development and regulatory work.
- The March financing provides for up to $130 million gross proceeds, including the initial $30 million, through warrants exercisable only upon specified milestones. The additional proceeds are contingent, not assured. At June 30, warrants represented approximately 160.96 million underlying preferred-share equivalents, presenting potential substantial dilution.
- After quarter-end, on July 11, 2023, Series A-1 preferred stock automatically converted, issuing 19,516,205 common shares. The company reported 34,752,221 common shares outstanding as of August 14, 2023.
- Disclosure controls and internal control over financial reporting were deemed ineffective due to a material weakness involving insufficient accounting staffing and expertise, inadequate formal procedures, and weaknesses in review and segregation of duties. Management planned remediation by year-end 2023.
- No material legal proceedings were reported. The filing reported no material changes to the risk factors in the 2022 Form 10-K.
Important facts for investors to verify
- Reconcile the six-month net loss and accumulated deficit: the financial statements report $18.413 million and $52.410 million, respectively, while portions of MD&A state $15.4 million and $49.3 million. The filing text does not clearly reconcile these figures.
- Track the FDA’s clarification of the required Oxylanthanum Carbonate trial, resulting cost and timeline, and implications for the stated cash runway.
- Confirm financing availability and the conditions, timing, and potential dilution associated with the preferred-stock warrants; distinguish contingent warrant proceeds from cash already raised.
- Monitor warrant-liability remeasurement, which depends on Level 3 assumptions and can cause large noncash swings in reported earnings.
- Assess progress on the disclosed control remediation and whether the accounting material weakness is resolved.